Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Report of the third meeting on "influenza vaccines that induce broad spectrum and long-lasting immune responses", World Health Organization, Geneva, Switzerland, 3-4 December 2007.

Girard MP, Osterhaus A, Pervikov Y, Palkonyay L, Kieny MP.

Vaccine. 2008 May 12;26(20):2443-50. doi: 10.1016/j.vaccine.2008.03.006. Epub 2008 Mar 28. No abstract available.

PMID:
18420316
2.

Influenza vaccines.

Clements ML.

Biotechnology. 1992;20:129-50. Review. No abstract available.

PMID:
1600379
3.

Attenuated influenza A viruses with modified cleavage sites in hemagglutinin as live vaccines.

Stech J.

Expert Rev Vaccines. 2008 Aug;7(6):739-43. doi: 10.1586/14760584.7.6.739. Review.

PMID:
18665773
4.

Influenza A (H5N1) pandemic prototype vaccine Fluval.

Vajo Z.

Expert Rev Vaccines. 2009 May;8(5):619-24. doi: 10.1586/erv.09.25. Review.

PMID:
19397418
5.

The immune response of humans to live and inactivated influenza vaccines.

Ghendon Y.

Adv Exp Med Biol. 1989;257:37-45. Review. No abstract available.

PMID:
2694822
6.

Influenza control in the 21st century: Optimizing protection of older adults.

Monto AS, Ansaldi F, Aspinall R, McElhaney JE, Montaño LF, Nichol KL, Puig-Barberà J, Schmitt J, Stephenson I.

Vaccine. 2009 Aug 13;27(37):5043-53. doi: 10.1016/j.vaccine.2009.06.032. Epub 2009 Jun 24. Review.

PMID:
19559118
7.

New vaccine approaches for seasonal and pandemic influenza.

Palache B.

Vaccine. 2008 Nov 18;26(49):6232-6. doi: 10.1016/j.vaccine.2008.07.022. Epub 2008 Jul 30. Review.

PMID:
18674583
8.

Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control.

Kreijtz JH, Osterhaus AD, Rimmelzwaan GF.

Hum Vaccin. 2009 Mar;5(3):126-35. Epub 2009 Mar 15. Review.

PMID:
18948744
9.

The Vaccine Formulation Laboratory: a platform for access to adjuvants.

Collin N, Dubois PM.

Vaccine. 2011 Jul 1;29 Suppl 1:A37-9. doi: 10.1016/j.vaccine.2011.04.125. Review.

10.

Emulsion-based adjuvants for influenza vaccines.

Vogel FR, Caillet C, Kusters IC, Haensler J.

Expert Rev Vaccines. 2009 Apr;8(4):483-92. doi: 10.1586/erv.09.5. Review.

PMID:
19348563
11.

WHO informal consultation on the scientific basis of specifications for production and control of inactivated Japanese encephalitis vaccines for human use, Geneva, Switzerland, 1-2 June 2006.

Ferguson M, Kurane I, Wimalaratne O, Shin J, Wood D; WHO informal consultation group.

Vaccine. 2007 Jul 20;25(29):5233-43. Epub 2007 Jun 8.

PMID:
17590244
12.

[Using reverse genetics method for developing recombinant strains of influenza viruses acceptable for use as live attenuated vaccines].

Merkulov VA, Lebedev VN, Plekhanova TM, Maksimov VA, Korovkin SA, Mironov AN.

Zh Mikrobiol Epidemiol Immunobiol. 2009 Mar-Apr;(2):111-7. Review. Russian.

PMID:
19462520
13.

Current status and progress of prepandemic and pandemic influenza vaccine development.

Leroux-Roels I, Leroux-Roels G.

Expert Rev Vaccines. 2009 Apr;8(4):401-23. doi: 10.1586/erv.09.15. Review.

PMID:
19348557
14.

IABs scientific workshop on neurovirulence tests for live virus vaccines, January 31-February 1, 2005, Geneva.

IABs.

Biologicals. 2006 Sep;34(3):233-6. Epub 2005 Oct 28. No abstract available.

PMID:
16257544

Supplemental Content

Support Center